Clinical trial · people
Thymogen (IM862): 8 of 25 kidney cancer patients had stable disease
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In this trial, IM862 given alone was well tolerated but did not shrink spreading kidney cancer, and the team advised against testing it further this way in these patients.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 25
- Published
- 2004
- Journal
- Br J Cancer
What they tested
The team tested whether IM862, the dipeptide also known as Thymogen, could shrink or control metastatic renal cell carcinoma (kidney cancer that has spread), and whether it was safe.
How the study was done
A prospective phase II trial with no comparison group in 25 adults with metastatic kidney cancer. Each person got IM862 intranasally (through the nose) at the trial's dose of 20 mg three times a day, in 8-week cycles.

What they found
None of the 25 patients had a significant objective response, meaning tumors did not shrink by a meaningful amount. 8 patients had stable disease (no growth) and 17 got worse while on treatment, with a median time to progression of 1.9 months and median survival of 7.9 months. Among 24 patients checked for side effects, none had grade 2 or 3 side effects tied to the drug. Blood levels of VEGF, a marker linked to blood vessel growth, fell significantly after 4 and 8 weeks.
What it doesn’t show
This was a small trial with no control arm, so it can't separate drug effects from the natural course of the disease. It tested only one dose and schedule, given alone, in one type of cancer.
The paper
Deplanque et al. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer. 2004.
The compound
More studies on Thymogen
- Thymogen (IM862): 36% major responses in AIDS-related Kaposi's sarcomaRandomized trial · people · 2000
- Every study on Thymogen
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.